Evidence map›Paper›PMID 36938236›Full record

ReviewCureus2023

Procedure, Screening, and Cost of Fecal Microbiota Transplantation.

Austin B Wynn, Garet Beyer, Megan Richards, Lisa A Ennis

Open access · diamondFull text readReview
In one paragraph

Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Austin B WynnPublic Health, Environmental Health, Informatics, Information Sciences, Alabama College of Osteopathic Medicine, Dothan, USA.
Garet BeyerPublic Health, Environmental Health, Informatics, Information Sciences, Alabama College of Osteopathic Medicine, Dothan, USA.
Megan RichardsPublic Health, Environmental Health, Informatics, Information Sciences, Alabama College of Osteopathic Medicine, Dothan, USA.
Lisa A EnnisPublic Health, Environmental Health, Informatics, Information Sciences, Alabama College of Osteopathic Medicine, Dothan, USA.
Alabama College of Osteopathic Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fecal microbiota transplantation (FMT) is currently considered a potential treatment for various GI-related illnesses, with the goal to replenish natural healthy flora of the GI tract that has been harmed because of antibiotic use or overgrowth of harmful bacteria. Current methods of administering the processed stool include colonoscopy and enema, while an oral capsule is being developed. Each method of administration carries its own set of risks, including adverse reactions to treatment, infection following the invasive administration procedure, and flare-ups of GI-related symptoms. Current oral administration through nasoduodenal tube poses a risk for aspiration which has not been ruled out as the cause of subsequent pneumonia and death in patient trials. The development of an oral capsule could address some of the faults of the current methods, not only making treatment more affordable and accessible but also less of a risk due to its minimally invasive nature. FMT is also a treatment option to attenuate adverse effects associated with antibiotic use, including combatting the emergence of antibiotic resistance, as well as adverse effects related to other medical treatments such as chemotherapy. While FMT is an unexplored treatment option for multiple gastrointestinal disorders and is currently still largely inaccessible for many patients financially, studies have suggested that it could be a more affordable treatment option long-term for patients as aspects of the treatment become more affordable with further research.

Indexed as

cost efficacyfecal microbiotafecal microbiota transplantation (fmt)procedure safetyscreening protocol

Identifiers

PMID36938236
PMCPMC10023044
OpenAlexW4321183731

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read5
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.